Leave Your Message
ADT1015-Aducanumab Biosimilar– Anti-APP Abeta mAb – Research Grade
Hot

ADT1015-Aducanumab Biosimilar– Anti-APP Abeta mAb – Research Grade

  • Catalog Number ADT1015
  • Host CHO Cells
  • Species Human
  • Target APP/Abeta
  • Application Elisa, WB

APP (Amyloid Beta Precursor Protein) is a Protein Coding gene. Among its related pathways are Toll Like Receptor 7/8 (TLR7/8) Cascade and GPCR downstream signalling.

Alpha Lifetech specializes in providing high-quality, highly active, and high-purity biosimilar antibody products.

Products Categories
Featured Products
recommended service
quick links
Contact Us

Product Background

APP (amyloid precursor protein) is a transmembrane glycoprotein measuring from 100 to 140 kDa. Protein precursor is a biological term, which refers to a class of protein-peptide chains synthesized by genes coding on the long arm of chromosome 21. Because of its hydrolysis break, a peptide chain called amyloid is composed of 40 to 42 amino acids, so it is called amyloid precursor and APP for short.  Under normal conditions, APP will be enzymatically decomposed into smaller fragments, including soluble APP α and soluble APP β, which can modulate neuronal function and survival, and APP β will be further processed and cleaved into Amyloid β.

Product Specification

Catalog Number

ADT1015

Product Name

ADT1015-Aducanumab Biosimilar– Anti-APP Abeta mAb – Research Grade

Alias

BART, BIIB-037

Isotype

IgG1 Kappa

Clonity

Monoclonal

Alternate Names

anti-APP antibody, APP antibody, amyloid precursor protein antibody, anti amyloid precursor protein antibody

Official Symbol

APP/Abeta

Species

Human

Expression Host

CHO Cells

Reactivity

Human

Gene ID

351

CAS Number

1384260-65-4

Molecular Weight

146.0 KDa

Product Description

Aducanumab, sold under the brand name Aduhelm, is a medication used to treat Alzheimer's disease (AD). It is an amyloid beta-directed monoclonal antibody. Aducanumab targets aggregated forms of Amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.

Mechanism of Action

Alzheimer's disease is a neurodegenerative disease. Part of the pathology of Alzheimer's disease is the presence of plaques forming extracellularly in the brain. These plaques are mostly composed of amyloid-β, a peptide of varying length formed by the cleavage of the amyloid precursor protein. The "amyloid cascade hypothesis" suggests that the accumulation of amyloid-β oligopeptides in the brain drives the pathogenesis of Alzheimer's disease.

Metabolism

Aducanumab is expected to be broken down into smaller oligopeptides and amino acids.

Size

100ug,1mg,5mg

Research Area

Neurobiology

Application

Elisa, WB

Purity

>95% as determined by SDS-PAGE

Concentration

Batch dependent

Buffer

Supplied in PBS, PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only. 

Reference

1.Poore AT, et al. Inorg Chem, 2023 Jul 10. PMID 37369063
2.Noguchi-Shinohara M, et al. Parkinsonism Relat Disord, 2023 Jun. PMID 37201326
3.Firouzi R, et al. Int J Mol Sci, 2023 May 3. PMID 37175868

 

FAQ

Leave Your Message